Navigation Links
Sudden Cardiac Arrest Association Honors FDNY's Department of Emergency Services for Efforts to Address Sudden Cardiac Arrest
Date:10/12/2009

CHICAGO, Oct. 12 /PRNewswire-USNewswire/ -- October is Sudden Cardiac Arrest Awareness Month, and the Sudden Cardiac Arrest Association (SCAA) honored the Fire Department of the City of New York (FDNY) Department of Emergency Services with the 2009 Medical Leadership Award for its efforts to raise awareness of sudden cardiac arrest (SCA), prevent sudden cardiac death and improve cardiovascular health. The award was presented at the SCAA Awards Dinner on Saturday, October 10, 2009, at the Hyatt Regency O'Hare in Chicago, Illinois, during the SCAA Annual Meeting.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091012/DC90763)

"The City of New York's leadership and the complex undertaking to implement these new protocols in the nation's largest city are noteworthy and have set the standard for other U.S. cities," said Chris Chiames, executive director of the Sudden Cardiac Arrest Association. "FDNY's expansion of therapeutic hypothermia treatment has led to a growing number of SCA survivors with positive neurologic outcomes and who are fully able to return to personal and professional routines and lead healthy, active and productive lives."

FDNY's "NYC Project Hypothermia" is the nation's largest EMS-led therapeutic hypothermia program to give SCA patients state-of-the-art pre-hospital and in-hospital care. The FDNY city-wide EMS 9-1-1 response protocol transports SCA patients directly to hospitals utilizing therapeutic hypothermia treatments and also begins cooling treatment in the field. Therapeutic hypothermia medically cools a cardiac arrest patient, allowing for a gradual, managed return of organ functions, and has been shown to greatly improve patient outcomes and minimize neurological damage often associated with the lack of oxygen immediately following collapse from SCA. At least 40 hospitals throughout New York City's five boroughs are participating in Phase I of the program which began in January. Phase II of the program, in which ambulances are equipped with therapeutic hypothermia devices such as specialized intravenous fluids, will be implemented in 2010.

The Sudden Cardiac Arrest Association (SCAA) is the largest non-profit advocacy organization exclusively focused on sudden cardiac arrest. SCAA identifies and unites survivors, those at risk of sudden cardiac arrest, as well as others who are interested in being advocates on SCAA issues in their communities. Its membership is dedicated to promoting solutions to prevent sudden cardiac death, including increased awareness, immediate bystander action, public access to defibrillation (PAD), and access to therapies. The SCAA Annual Meeting in Chicago brings together volunteers from nearly 50 chapters and affiliates from across the country, including SCA survivors, physicians, nurses, emergency professionals and others touched by SCA. To learn more, visit www.suddencardiacarrest.org.

SOURCE Sudden Cardiac Arrest Association


'/>"/>
SOURCE Sudden Cardiac Arrest Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
2. Study Sheds Light on Origins of Sudden Cardiac Death
3. Sudden Cardiac Arrest Association Launches Austin and Lubbock Chapters
4. Sudden Cardiac Arrest Association Launches Iowa Affiliate
5. Sudden Cardiac Arrest Association Launches Its First Thirteen Local Chapters/Affiliates
6. Sudden Cardiac Arrest Association Launches Kansas City Chapter
7. Sudden Cardiac Arrest Association Launches Long Island and Queens Chapters
8. Sudden Cardiac Arrest Association Launches South Florida Chapter
9. Sudden Cardiac Arrest Association Launches Southwest Connecticut Chapter
10. Sudden Cardiac Arrest Association Launches Two Minnesota Affiliates
11. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: